AAPL281.74-2.04 (-0.72%) ▼|ABBV254.31+0.96 (+0.38%) ▲|ABT92.71-1.41 (-1.50%) ▼|ACN124.74-4.24 (-3.29%) ▼|ADBE206.43+3.70 (+1.83%) ▲|AMAT694.64+67.80 (+10.82%) ▲|AMD539.49+17.91 (+3.43%) ▲|AMGN360.55+2.22 (+0.62%) ▲|AMT168.67-6.92 (-3.94%) ▼|AMZN240.14+7.45 (+3.20%) ▲|AVGO372.45+7.43 (+2.04%) ▲|AXP340.88+0.52 (+0.15%) ▲|BA214.69-2.56 (-1.18%) ▼|BAC57.88+0.00 (+0.00%) ▲|BKNG182.41+0.95 (+0.52%) ▲|BLK950.17-14.54 (-1.51%) ▼|BMY58.56+1.04 (+1.81%) ▲|BNY143.80+0.24 (+0.17%) ▲|BRK-B496.00-2.66 (-0.53%) ▼|C142.49+0.73 (+0.52%) ▲|CAT1,033.19+35.72 (+3.58%) ▲|CL92.40+0.33 (+0.36%) ▲|CMCSA24.22+1.05 (+4.53%) ▲|COF202.28-1.72 (-0.84%) ▼|COP104.20-1.76 (-1.66%) ▼|COST946.68-5.86 (-0.62%) ▼|CRM157.93-0.44 (-0.28%) ▼|CSCO117.70+3.93 (+3.45%) ▲|CVS103.58-0.76 (-0.73%) ▼|CVX168.47-2.59 (-1.51%) ▼|DE626.63+13.39 (+2.18%) ▲|DHR192.78-3.41 (-1.74%) ▼|DIS98.63-0.16 (-0.16%) ▼|DUK128.33-0.07 (-0.05%) ▼|EMR142.82-0.67 (-0.47%) ▼|FDX325.40+6.87 (+2.16%) ▲|GD348.07+1.36 (+0.39%) ▲|GE373.71+4.71 (+1.28%) ▲|GEV1,102.51+57.34 (+5.49%) ▲|GILD126.33-1.55 (-1.21%) ▼|GM77.34-0.76 (-0.97%) ▼|GOOG351.28+16.59 (+4.96%) ▲|GOOGL353.65+16.26 (+4.82%) ▲|GS1,020.21+0.60 (+0.06%) ▲|HD350.81+1.95 (+0.56%) ▲|HON227.80-15.61 (-6.41%) ▼|IBM278.00+6.37 (+2.35%) ▲|INTC131.72+3.40 (+2.65%) ▲|INTU266.40-1.32 (-0.49%) ▼|ISRG405.97+1.70 (+0.42%) ▲|JNJ258.51+3.85 (+1.51%) ▲|JPM329.39+0.34 (+0.10%) ▲|KO82.65+0.02 (+0.02%) ▲|LIN511.06-8.56 (-1.65%) ▼|LLY1,229.93+21.81 (+1.81%) ▲|LMT502.07-5.33 (-1.05%) ▼|LOW219.65-2.83 (-1.27%) ▼|LRCX410.91+31.82 (+8.39%) ▲|MA509.64+10.62 (+2.13%) ▲|MCD267.18-2.58 (-0.96%) ▼|MDLZ60.15-0.64 (-1.05%) ▼|MDT80.93-0.05 (-0.06%) ▼|META562.60+12.35 (+2.24%) ▲|MMM162.43-1.58 (-0.96%) ▼|MO74.05+0.26 (+0.35%) ▲|MRK129.38+0.72 (+0.56%) ▲|MS211.72-0.31 (-0.15%) ▼|MSFT368.57-4.40 (-1.18%) ▼|MU1,145.28+12.95 (+1.14%) ▲|NEE88.66+0.10 (+0.11%) ▲|NFLX73.78-0.03 (-0.04%) ▼|NKE41.48+0.73 (+1.79%) ▲|NOW99.97+1.63 (+1.66%) ▲|NVDA194.97+2.44 (+1.27%) ▲|ORCL147.76-0.77 (-0.52%) ▼|PEP138.68-2.71 (-1.92%) ▼|PFE24.37+0.08 (+0.33%) ▲|PG148.45-0.57 (-0.38%) ▼|PLTR115.70+2.77 (+2.45%) ▲|PM182.87+2.10 (+1.16%) ▲|QCOM188.72-0.67 (-0.35%) ▼|RTX187.33-0.66 (-0.35%) ▼|SBUX104.06-0.54 (-0.52%) ▼|SCHW90.55-0.12 (-0.13%) ▼|SO96.75-0.41 (-0.42%) ▼|SPG227.56+0.67 (+0.30%) ▲|T21.82-0.90 (-3.96%) ▼|TMO506.42-6.61 (-1.29%) ▼|TMUS173.97-8.71 (-4.77%) ▼|TSLA411.84+32.13 (+8.46%) ▲|TXN285.48+0.06 (+0.02%) ▲|UBER75.50-0.70 (-0.92%) ▼|UNH419.82-8.07 (-1.89%) ▼|UNP272.70+4.35 (+1.62%) ▲|UPS108.01-0.13 (-0.12%) ▼|USB61.28+0.37 (+0.61%) ▲|V341.65+5.42 (+1.61%) ▲|VZ44.10-2.44 (-5.24%) ▼|WFC83.51-0.35 (-0.42%) ▼|WMT114.60-1.09 (-0.94%) ▼|XOM136.06-0.48 (-0.35%) ▼|AAPL281.74-2.04 (-0.72%) ▼|ABBV254.31+0.96 (+0.38%) ▲|ABT92.71-1.41 (-1.50%) ▼|ACN124.74-4.24 (-3.29%) ▼|ADBE206.43+3.70 (+1.83%) ▲|AMAT694.64+67.80 (+10.82%) ▲|AMD539.49+17.91 (+3.43%) ▲|AMGN360.55+2.22 (+0.62%) ▲|AMT168.67-6.92 (-3.94%) ▼|AMZN240.14+7.45 (+3.20%) ▲|AVGO372.45+7.43 (+2.04%) ▲|AXP340.88+0.52 (+0.15%) ▲|BA214.69-2.56 (-1.18%) ▼|BAC57.88+0.00 (+0.00%) ▲|BKNG182.41+0.95 (+0.52%) ▲|BLK950.17-14.54 (-1.51%) ▼|BMY58.56+1.04 (+1.81%) ▲|BNY143.80+0.24 (+0.17%) ▲|BRK-B496.00-2.66 (-0.53%) ▼|C142.49+0.73 (+0.52%) ▲|CAT1,033.19+35.72 (+3.58%) ▲|CL92.40+0.33 (+0.36%) ▲|CMCSA24.22+1.05 (+4.53%) ▲|COF202.28-1.72 (-0.84%) ▼|COP104.20-1.76 (-1.66%) ▼|COST946.68-5.86 (-0.62%) ▼|CRM157.93-0.44 (-0.28%) ▼|CSCO117.70+3.93 (+3.45%) ▲|CVS103.58-0.76 (-0.73%) ▼|CVX168.47-2.59 (-1.51%) ▼|DE626.63+13.39 (+2.18%) ▲|DHR192.78-3.41 (-1.74%) ▼|DIS98.63-0.16 (-0.16%) ▼|DUK128.33-0.07 (-0.05%) ▼|EMR142.82-0.67 (-0.47%) ▼|FDX325.40+6.87 (+2.16%) ▲|GD348.07+1.36 (+0.39%) ▲|GE373.71+4.71 (+1.28%) ▲|GEV1,102.51+57.34 (+5.49%) ▲|GILD126.33-1.55 (-1.21%) ▼|GM77.34-0.76 (-0.97%) ▼|GOOG351.28+16.59 (+4.96%) ▲|GOOGL353.65+16.26 (+4.82%) ▲|GS1,020.21+0.60 (+0.06%) ▲|HD350.81+1.95 (+0.56%) ▲|HON227.80-15.61 (-6.41%) ▼|IBM278.00+6.37 (+2.35%) ▲|INTC131.72+3.40 (+2.65%) ▲|INTU266.40-1.32 (-0.49%) ▼|ISRG405.97+1.70 (+0.42%) ▲|JNJ258.51+3.85 (+1.51%) ▲|JPM329.39+0.34 (+0.10%) ▲|KO82.65+0.02 (+0.02%) ▲|LIN511.06-8.56 (-1.65%) ▼|LLY1,229.93+21.81 (+1.81%) ▲|LMT502.07-5.33 (-1.05%) ▼|LOW219.65-2.83 (-1.27%) ▼|LRCX410.91+31.82 (+8.39%) ▲|MA509.64+10.62 (+2.13%) ▲|MCD267.18-2.58 (-0.96%) ▼|MDLZ60.15-0.64 (-1.05%) ▼|MDT80.93-0.05 (-0.06%) ▼|META562.60+12.35 (+2.24%) ▲|MMM162.43-1.58 (-0.96%) ▼|MO74.05+0.26 (+0.35%) ▲|MRK129.38+0.72 (+0.56%) ▲|MS211.72-0.31 (-0.15%) ▼|MSFT368.57-4.40 (-1.18%) ▼|MU1,145.28+12.95 (+1.14%) ▲|NEE88.66+0.10 (+0.11%) ▲|NFLX73.78-0.03 (-0.04%) ▼|NKE41.48+0.73 (+1.79%) ▲|NOW99.97+1.63 (+1.66%) ▲|NVDA194.97+2.44 (+1.27%) ▲|ORCL147.76-0.77 (-0.52%) ▼|PEP138.68-2.71 (-1.92%) ▼|PFE24.37+0.08 (+0.33%) ▲|PG148.45-0.57 (-0.38%) ▼|PLTR115.70+2.77 (+2.45%) ▲|PM182.87+2.10 (+1.16%) ▲|QCOM188.72-0.67 (-0.35%) ▼|RTX187.33-0.66 (-0.35%) ▼|SBUX104.06-0.54 (-0.52%) ▼|SCHW90.55-0.12 (-0.13%) ▼|SO96.75-0.41 (-0.42%) ▼|SPG227.56+0.67 (+0.30%) ▲|T21.82-0.90 (-3.96%) ▼|TMO506.42-6.61 (-1.29%) ▼|TMUS173.97-8.71 (-4.77%) ▼|TSLA411.84+32.13 (+8.46%) ▲|TXN285.48+0.06 (+0.02%) ▲|UBER75.50-0.70 (-0.92%) ▼|UNH419.82-8.07 (-1.89%) ▼|UNP272.70+4.35 (+1.62%) ▲|UPS108.01-0.13 (-0.12%) ▼|USB61.28+0.37 (+0.61%) ▲|V341.65+5.42 (+1.61%) ▲|VZ44.10-2.44 (-5.24%) ▼|WFC83.51-0.35 (-0.42%) ▼|WMT114.60-1.09 (-0.94%) ▼|XOM136.06-0.48 (-0.35%) ▼|
28.7 C
New York
Tuesday, June 30, 2026

Tag: cancer

newssourceFORcompanyinformationcontent1releasesmarket

Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress

ROCKVILLE, Md. and SUZHOU, China, June 09, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that 13 studies of its core assets - including the novel drug olverembatinib (HQP1351), the investigational Bcl-2 inhibitor lisaftoclax (APG-2575), and the investigational EED inhibitor APG-5918 – will be featured in an oral presentation, multiple poster presentations and multiple online publications at the 2025 European Hematology Association (EHA) Annual Congress taking place in Milan, Italy, from June 12-15, 2025.

Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025

First presentation of the Phase 4 XYLO switch study reports blood pressure reductions in patients with narcolepsy when switching from twice-nightly high- to low-sodium...

HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034) | DelveInsight

The overall HER2+ gastric cancer market is projected to grow, driven by increasing biomarker testing, better patient selection, and continued advancements in HER2-targeted ADCs,...

Senti Biosciences Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that on June 3, 2025 Senti Bio’s Board of Directors granted to eight new employees stock options to purchase an aggregate of 102,500 shares of the Company’s common stock with a per share exercise price of $3.03. These awards were made under the Company’s Amended and Restated 2022 Inducement Equity Plan (the “Plan”).

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced the appointment of Mark J. Bachleda, PharmD, MBA as an independent member of the Board of Directors, David Shook, MD as Chief Medical Officer, and Mark Meltz, JD as General Counsel and Corporate Secretary. These appointments, along with the appointment earlier in the year of Jarrad Aguirre, MD, MBA as Senior Vice President, Medical Affairs, further strengthen the Company’s clinical and commercial capabilities.

Canadian Nuclear Laboratories and the University of Ottawa Accelerate Low Dose Radiation Research and Foster Next Generation of Scientists

New partnership furthers Canada’s international leadership in low dose radiation research 
New partnership furthers Canada’s international leadership in low dose radiation research

Les Laboratoires nucléaires canadiens et l’Université d’Ottawa accélèrent la recherche sur le rayonnement à faible dose et font progresser la prochaine génération de scientifiques

Un nouveau partenariat renforce le leadership international du Canada dans la recherche sur le rayonnement à faible dose 
Un nouveau partenariat renforce le leadership international du Canada dans la recherche sur le rayonnement à faible dose

Myosin Therapeutics Receives FDA Clearance to Initiate First-in-Human Trial of MT-125 in Glioblastoma

JUPITER, Fla., June 9, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies targeting molecular motors, today announced that the...

AS JUNE 19 WORLD SICKLE CELL AWARENESS DAY APPROACHES, COLLABORATIVE OF 47 COMMUNITY-BASED ORGANIZATIONS AND MEDICAL PROVIDERS PREPARE TO ‘SHINE THE LIGHT ON SICKLE...

COMMUNITY ACTION CAMPAIGN TO ILLUMINATE COMMUNITIES, RAISE AWARENESS, CALL FOR A UNIVERSAL CURE IN SUPPORT OF SICKLE CELL WARRIORS Historically African American Sororities And Fraternities...

tcmc to Showcase Asia’s Leading Cell & Gene Therapy CDMO Capabilities at BIO International Convention

BOSTON, June 9, 2025 /PRNewswire/ -- Taiwan Cell Manufacturing Company (tcmc), a leading Contract Development and Manufacturing Organization (CDMO) in cell and gene therapy...

Medicovestor, Inc. and Sanyou Biopharmaceuticals Forge Strategic Partnership to Develop First-in-Class Chemoimmunotherapy Antibody-Drug Conjugates

Medicovestor and Sanyou team up to develop first-in-class chemoimmunotherapy ADCs, combining AI antibody tech with novel dual-targeting platforms.

MD Anderson and HealthEx Announce Collaboration to Develop New Platform to Give Patients Direct Control of Data Access

The University of Texas MD Anderson Cancer Center and HealthEx are developing an AI platform to give patients more control in how their data is used.

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

Agreement supports the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma CRANFORD, N.J., June 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology")...

Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants

-- Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCancer

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers